Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the prostate

2. High risk localized adenocarcinoma defined by at least one of the following criteria:

- Clinical stage T2c, T3 or T4

- Gleason score ≥ 8

- Prostate-specific antigen (PSA)≥ 20 ng/ml and ≤ 100 ng/ml

3. Patient cN0, pN0 or Nx (negative lymphadenectomy or no lymphadenectomy)

4. No pelvic adenopathy ≥ 15 mm on CT or MRI,

5. Absence of bone and/or visceral metastasis

6. Androgen deprivation beginning no later than the day of radiotherapy and up to six
months before irradiation

7. Absence of prior pelvic radiotherapy,

8. Absence of surgical treatment of prostate cancer except transurethral resection
performed within 4 months minimum before radiotherapy,

9. Age ≥ 18 years and ≤ 80 years

10. ECOG performance status ≤ 1,

11. Estimated life expectancy > 5 years

12. Membership of a social security system,

13. Signed informed consent.

Exclusion Criteria:

1. Prostate cancer histology other than adenocarcinoma,

2. pN1 patients (lymph node dissection after histologically proven)

3. PSA > 100 ng/ml

4. History of cancer within 5 years prior to trial entry (with the exception of basal
cell carcinoma skin)

5. Patient with severe hypertension uncontrolled by appropriate treatment (≥ 160 mm Hg
systolic and / or ≥ 90 mm Hg diastolic)

6. Contra-indication for pelvic irradiation (eg scleroderma, chronic inflammatory
disease of the digestive tract, etc ...)

7. Contra-indication to agonists of LH-RH

8. Bilateral hip prosthesis,

9. Patients already included in another clinical trial with an experimental molecule,

10. Persons deprived of liberty or under guardianship

11. Unable to undergo medical test for geographical, social or psychological.